193 related articles for article (PubMed ID: 33093155)
21. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
22. Immunoliposomes bearing lymphocyte activation gene 3 fusion protein and P5 peptide: A novel vaccine for breast cancer.
Mohammadian Haftcheshmeh S; Zamani P; Mashreghi M; Nikpoor AR; Tavakkol-Afshari J; Jaafari MR
Biotechnol Prog; 2021 Mar; 37(2):e3095. PubMed ID: 33118322
[TBL] [Abstract][Full Text] [Related]
23. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
24. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
25. PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes.
Putz EM; Prchal-Murphy M; Simma OA; Forster F; Koenig X; Stockinger H; Piekorz RP; Freissmuth M; Müller M; Sexl V; Zebedin-Brandl E
PLoS One; 2012; 7(7):e40852. PubMed ID: 22808277
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients.
Ma Q; Liu J; Wu G; Teng M; Wang S; Cui M; Li Y
Clin Exp Pharmacol Physiol; 2018 Oct; 45(10):1002-1009. PubMed ID: 29905955
[TBL] [Abstract][Full Text] [Related]
27. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
28. Lymphocyte-activation gene 3(+) (LAG3(+)) forkhead box protein 3(-) (FOXP3(-)) regulatory T cells induced by B cells alleviates joint inflammation in collagen-induced arthritis.
Chen SY; Hsu WT; Chen YL; Chien CH; Chiang BL
J Autoimmun; 2016 Apr; 68():75-85. PubMed ID: 26908164
[TBL] [Abstract][Full Text] [Related]
29. Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells.
Somasundaram A; Cillo AR; Lampenfeld C; Workman CJ; Kunning S; Oliveri L; Velez M; Joyce S; Calderon M; Dadey R; Rajasundaram D; Normolle DP; Watkins SC; Herman JG; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Vignali DAA
Cancer Immunol Res; 2022 Jul; 10(7):885-899. PubMed ID: 35587532
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
31. Function and regulation of LAG3 on CD4
Ma QY; Huang DY; Zhang HJ; Wang S; Chen XF
Exp Cell Res; 2017 Nov; 360(2):358-364. PubMed ID: 28935468
[TBL] [Abstract][Full Text] [Related]
32. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
Cao L; Dai C; Qin R; Guo Y; Liu J
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
[No Abstract] [Full Text] [Related]
33. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.
Davis RJ; Moore EC; Clavijo PE; Friedman J; Cash H; Chen Z; Silvin C; Van Waes C; Allen C
Cancer Res; 2017 May; 77(10):2607-2619. PubMed ID: 28364000
[TBL] [Abstract][Full Text] [Related]
34. TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses.
Okamura T; Sumitomo S; Morita K; Iwasaki Y; Inoue M; Nakachi S; Komai T; Shoda H; Miyazaki J; Fujio K; Yamamoto K
Nat Commun; 2015 Feb; 6():6329. PubMed ID: 25695838
[TBL] [Abstract][Full Text] [Related]
35. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
37. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
38. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
[TBL] [Abstract][Full Text] [Related]
39. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
40. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
